An observational study in Depressive Symptoms and Suicidal Ideation, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Stanford University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Depression by Stanford University — 15 open to participants now, 17 under way, none of them phase 3. Depression · Stanford University.
Among the 77 studies in Depression by Stanford University, this one is the 12th largest by enrollment of the 12 observational ones that give a count, is one of 4 that started in 2018, is one of 12 observational ones, and was the 41st registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →15 of the 77 studies in Depression by Stanford University are open now, in 2 countries. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 5–14
Stanford University · Sites in United States
Ages 18–60
Stanford University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 65+
Stanford University · Sites in United States
Ages 18–80
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 3 · Phase 4 5
First in 1999; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 175 across 1,261 observational studies indexed under Depression.
Median enrollment 40 across the 64 interventional studies, 87 across the 12 observational. Of the 53 that completed or were terminated, 17 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
9 of the studies in Depression by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06317636Stanford UniversityPropofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression | 2026-11 |
| NCT07188623Stanford UniversityVirtual Reality-Enhanced Behavioral Activation for Older Adults With Depression | 2026-12 |
| NCT04870255Stanford UniversityTreatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS | 2026-12 |
| NCT06430853Stanford UniversityPsychobiological Interventions in Pregnancy | 2027-01-01 |
| NCT06373718Stanford UniversitySleep Mechanisms Of Regulating Emotions | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 77 studies in Depression by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will monitor the symptoms of patients who have received an intervention on the psychiatric inpatient unit at Stanford hospital up to 6 months after they have received the intervention. Additionally, the acceptability and feasibility of interventions will be assessed using clinician and patient questionnaires.
Once patients have been discharged from hospital they will be contacted weekly for 4 weeks and then every 2 weeks until 6 months post-intervention in order to monitor their symptoms. Participants will be followed up until the end of the study (6 months after the intervention) or until they no longer meet responder criteria (MADRS score>50% of score before they received the intervention) During the follow-ups for the first 8 weeks, the following assessments will be conducted: Montgomery-Åsberg Depression Rating Scale (MADRS) Scale of suicidal ideation (SSI) Hamilton depression rating scale (HAMD-6) Young Mania Rating Scale (YMRS) Pittsburgh insomnia rating scale (PIRS-20) Quick inventory of depressive symptomatology (QIDS) Immediate Mood Scaler (IMS-12) Beck Depression Inventory (BDI-II) C-SSRS self-report short version
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) will be collected at one month post-intervention.
If the participant has a psychiatric diagnosis(/es) other than MDD, questionnaires measuring the symptoms associated with the participant's other psychiatric diagnosis/(es) will also be administered.
Follow-up assessments from 10-24 weeks will include:
MADRS SSI BDI-II C-SSRS self-report short version
If the participant has a psychiatric diagnosis other than MDD, questionnaires measuring the symptoms associated with the participant's other psychiatric diagnosis/(es) will also be administered.
The questionnaires that will be used to assess symptoms associated with primary psychiatric diagnoses are:
At all time points, information regarding medication changes and other psychiatric treatments will be collected.
Patients admitted to the psychiatric unit at Stanford University displaying depressive symptoms or suicidal ideation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-None
Patients who have received accelerated theta burst stimulation delivered to the left dorsolateral prefrontal cortex on the inpatient unit at Stanford
Patients who have received accelerated theta burst stimulation delivered to the anterior cingulate cortex on the inpatient unit at Stanford
Patients who have received ECT on the inpatient unit at Stanford
Montgomery-Asberg Depression Rating Scale (MADRS)
This is a ten-item clinician rated questionnaire in which the clinician rates each item from 0-6. Scores of 6 indicate more severe depressive symptoms. Total scores are between 0 and 60 with scores \>35 indicating severe depression. Response is defined as a 50% reduction or greater in MADRS score compared to baseline. Remission is defined as a MADRS score of \<10.
Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 24 weeks post-intervention
Scale for Suicide Ideation (SSI)
Clinical assessment measuring suicidal thoughts \& behaviors
Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 24 weeks post-intervention
Beck Depression Inventory II (BDI-II)
The Beck Depression Inventory (BDI-II) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63. Scores: 0-13= minimal depression, 14-19=mild depression, 20-28=moderate depression, 29-63=severe depression
Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 24 weeks post-intervention
Columbia-Suicide Severity Rating Scale (C-SSRS)
Self-report questionnaire identifying the presence or absence of six suicidal thoughts or behaviors in the past month or since the last visit. Each 'yes' answer is scored as 1, meaning the maximum total score is 6. The scale identifies specific behaviors which may be indicative of a person's intent to complete suicide. An person exhibiting even a single behavior identified by the scale was 8 to 10 times more likely to complete suicide.
Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 24 weeks post-intervention
Young Mania Rating Scale (YMRS)
11-item multiple choice clinician-rated questionnaire. Each question is rated from 0 to 4 with 4
Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 8 weeks post-intervention.
Pittsburgh Insomnia Rating Scale (PIRS-20)
Self-report insomnia rating scale
Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 8 weeks post-intervention.
Hamilton Rating Scale for Depression Six Item (HAMD-6)
Response is defined as a 50% reduction or greater in HAMD-6 score compared to baseline. HAMD-6 is a 6-item clinical assessment measuring depressive symptoms (scores range from 0-24 with scores of 5 or more indicating clinical levels of depression). The number of weeks in which HAMD-6 scores are lower than 50% of baseline will be calculated to provide a measure of duration of response.
Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 8 weeks post-intervention.
Quick Inventory Depressive Symptomatology (QIDS)
Self-report measure of depressive symptoms
Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 8 weeks post-intervention.
Immediate Mood Scaler (IMS-12)
12-item self-report questionnaire used to measure current mood
Time frame: weekly for first 4 weeks, followed by bi-weekly up until 8 weeks post-intervention.
Number of hospital re-admissions and service use
The number of times patients are re-admitted to hospital and used psychiatric services since the last assessment will be recorded
Time frame: Bi-weekly up until 24 weeks post-intervention
Plan to share: No
Ran from Jul 2018 to primary completion in Apr 2023, 56 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2024 → Apr 2023 and completion Dec 2025 → Apr 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.